How should Barrett's esophagus be managed?

Management of Barrett's Esophagus

Barrett's esophagus should be managed with endoscopic surveillance using high-resolution white light endoscopy with Seattle protocol biopsies, combined with acid suppression therapy for symptom control, with treatment escalating to endoscopic eradication therapy when dysplasia is detected. 1

Initial Patient Consultation and Education

• Offer a clinical consultation at diagnosis to discuss cancer risk, surveillance plans, and symptom management 1
• Provide both verbal and written information about the diagnosis, treatment options, and patient support groups 1
• After each surveillance procedure, provide an endoscopy report with a lay summary of findings 1

Symptom Control

• Follow standard GORD management recommendations with proton pump inhibitor therapy for acid suppression 1, 2
• Do not offer aspirin specifically to prevent progression to dysplasia or cancer 1
• Do not offer anti-reflux surgery to prevent progression to dysplasia or cancer 1

Endoscopic Surveillance Strategy

Surveillance Technique

• Use high-resolution white light endoscopy with Seattle biopsy protocol (4-quadrant biopsies every 2 cm) 1
• Take specific biopsy specimens of any mucosal irregularities and submit them separately to pathology 1
• Ensure the benefits of surveillance outweigh risks based on the patient's overall health status 1

Surveillance Intervals Based on Dysplasia Grade

For non-dysplastic Barrett's esophagus:

• Surveillance every 3-5 years 1, 3

For low-grade dysplasia:

• Surveillance every 6-12 months 1
• Alternatively, offer radiofrequency ablation after confirmation by two separate endoscopies with two gastrointestinal pathologists confirming the diagnosis 1

For indefinite dysplasia:

• Consider surveillance at 6-month intervals with dose optimization of acid-suppressant medication 1

For high-grade dysplasia:

• Surveillance every 3 months if no eradication therapy is performed 1
• However, endoscopic treatment is preferred over surveillance alone (see below) 1

Management of Barrett's Esophagus with Dysplasia

High-Grade Dysplasia

• Offer endoscopic resection of visible lesions as first-line treatment 1
• Follow with endoscopic ablation of any residual Barrett's esophagus after resection 1
• Provide endoscopic follow-up after treatment 1

Low-Grade Dysplasia

• Offer radiofrequency ablation after diagnosis confirmed on biopsy samples from two separate endoscopies, with two gastrointestinal pathologists confirming the histological diagnosis 1
• Endoscopic surveillance remains an acceptable alternative 3

Indefinite Dysplasia

• Perform endoscopic surveillance at 6-month intervals with optimized acid suppression 1

Management of Stage 1 Esophageal Adenocarcinoma

Staging Approach

• Offer endoscopic resection for staging of suspected stage 1 adenocarcinoma 1
• Do not use CT before endoscopic resection for staging suspected T1 disease 1
• Do not use endoscopic ultrasonography (EUS) before endoscopic resection for staging T1a disease 1
• Consider EUS for nodal staging in suspected or confirmed T1b disease 1

Treatment by T Stage

T1a adenocarcinoma:

• Offer endoscopic resection as first-line treatment 1
• Follow with endoscopic ablation of residual Barrett's esophagus 1
• Provide endoscopic follow-up after treatment 1

T1b adenocarcinoma:

• Offer oesophagectomy to patients who are fit for surgery and at high risk of cancer progression (incomplete endoscopic resection, lymphovascular invasion, or deep submucosal invasion >500 μm) 1
• Consider radiotherapy (alone or with chemotherapy) for patients at high risk who are unfit for oesophagectomy 1
• Offer endoscopic follow-up after radiotherapy 1

Key Pitfalls and Caveats

Pathology interpretation challenges:

• Low-grade dysplasia is frequently overcalled by community pathologists, especially when esophageal inflammation is present 1
• Expert pathology review is critical, particularly for initial diagnoses of dysplasia 1, 2

Biomarkers:

• Do not use molecular biomarkers to confirm dysplasia or for risk stratification at this time, as they lack sufficient validation 1

Surveillance adherence:

• Many gastroenterologists do not adhere to recommended biopsy protocols, with poorest adherence in highest-risk populations (extensive Barrett's metaplasia) 1
• Adherence to Seattle protocol biopsies is associated with higher rates of dysplasia and cancer detection 1

Competing mortality:

• Barrett's patients are 10 times more likely to die from non-cancer causes than esophageal cancer 4
• Consider overall health status and life expectancy when deciding on surveillance intensity 1, 4